glp-1 obesity drugs updates today Weight Loss Drug Market Size, Share Anti-Obesity Drug Market Size and

Nauck MA, Meier JJ (2019) Are all GLP-1 agonists equal in the treatment of type 2 diabetes

Patients With Established Cardiovascular Disease Injectable semaglutide currently has more mature cardiovascular outcome data

proposed that ventilatory depression in Insulin-dependent diabetes mellitus (IDDM) is dependent on a reduction in circulating leptin levels [40]

Till Giese and Iryna Scheurlen GLP-1 receptor agonists have surged into the spotlight for their remarkable effectiveness in managing type 2 diabetes and obesity

20 Our understanding suggests that drawing comparisons between different trials hints at a shared method of action

PMID: Summary Keywords biologic therapy, early psoriatic arthritis, GLP-1 receptor agonists, inflammation, metabolic syndrome, psoriasis Citation Ciancio G, Maranini B, Sandri G, Amati G, Bortoluzzi A, Silvagni E, Govoni M and Giuggioli D (2026) Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities